MeiraGTx Holdings PLC
$ 9.59
-0.10%
12 Jun - close price
- Market Cap 888,125,000 USD
- Current Price $ 9.59
- High / Low $ 9.84 / 9.53
- Stock P/E N/A
- Book Value -0.71
- EPS -1.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -3.68 %
- 52 Week High 11.85
- 52 Week Low 6.07
About
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Analyst Target Price
$28.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-13 | 2024-11-13 | 2024-08-12 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.57 | 0.19 | -0.62 | -0.48 | -0.51 | -0.5 | -0.55 | -0.76 | -0.32 | -0.42 | -0.74 | -0.53 |
| Estimated EPS | -0.4475 | -0.564 | -0.5 | -0.4733 | -0.5 | -0.56 | -0.52 | -0.4 | -0.5 | -0.11 | -0.55 | -0.57 |
| Surprise | -0.1225 | 0.754 | -0.12 | -0.0067 | -0.01 | 0.06 | -0.03 | -0.36 | 0.18 | -0.31 | -0.19 | 0.04 |
| Surprise Percentage | -27.3743% | 133.6879% | -24% | -1.4156% | -2% | 10.7143% | -5.7692% | -90% | 36% | -281.8182% | -34.5455% | 7.0175% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGTX
2026-06-11 23:39:20
MeiraGTx Holdings plc director Harris Keith R. converted 75,000 restricted share units (RSUs) into 75,000 ordinary shares without a reported purchase price. This transaction increased his direct holdings to 200,000 ordinary shares. The conversion, detailed in a Form 4 SEC filing, represents a routine equity settlement rather than an open-market trade.
2026-06-11 17:41:01
MeiraGTx Holdings PLC (MGTX) reported a Q1 loss, missing revenue estimates. The company's financial performance fell short of analyst expectations for the quarter.
2026-06-09 14:40:34
MeiraGTx Holdings (MGTX) recently garnered significant attention after the FDA granted Breakthrough Therapy Designation to its AAV2-hAQP1 program, aimed at treating radiation-induced xerostomia. This development, which can accelerate the drug's path to market, caused the stock to move sharply in extended trading, highlighting the sensitivity of biotech shares to regulatory news. The company is a clinical-stage gene therapy firm focused on high-unmet-need areas, and its value is largely dependent on pipeline milestones and FDA actions rather than current revenue.
2026-06-05 15:02:00
MeiraGTx Holdings plc (MGTX) presented a slideshow at the Jefferies Global Healthcare Conference 2026. The article highlights that the presentation materials were published by the company in conjunction with this event. The content was provided by SA Transcripts, which focuses on earnings call transcripts and related projects.
2026-06-02 03:39:38
MeiraGTx Holdings plc has announced an amendment to its $100,000,000 fluctuating rate senior secured loan notes. The amendment extends the maturity date of these notes from May 2, 2027, to July 1, 2027. This change was implemented via a Deed of Amendment to the original Note Purchase Agreement dated December 19, 2022.
2026-05-29 01:39:37
MeiraGTx Holdings plc's CFO & COO, Richard Giroux, reported a bona fide gift of 7,000 Ordinary Shares. Following this transaction, Giroux directly holds 964,530 Ordinary Shares, with additional indirect holdings through Aigle Healthcare Partners III LLC and his spouse. The transaction is marked as a gift (transaction code G), meaning no monetary value was exchanged.
